Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3355963 | 0.98 | PRKCI (0.39) | PRKCICA12ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3352601 | 0.98 | PRKCI (0.39) | PRKCICA12ALDH1A1MEN1KMT2A | |
| Acetic Acid SCHEMBL6139766 | 0.95 | PRKCI (0.41) | PRKCICA12ALDH1A1MEN1KMT2A | |
| Formamide SCHEMBL6342969 | 0.94 | PRKCI (0.36) | PRKCICA12ALDH1A1MEN1KMT2A | |
| SCHEMBL5349926 | 0.90 | PRKCI (0.38) | PRKCICA12PTPN1PTPN11 | |
| Trifluoroacetic Acid SCHEMBL6647805 | 0.90 | PRKCI (0.34) | PRKCICA12ALDH1A1MEN1KMT2A | |
| SCHEMBL7123990 | 0.86 | PRKCI (0.40) | PRKCICA12ALDH1A1MEN1KMT2A | |
| SCHEMBL6187624 | 0.86 | ALDH1A1 (0.37) | PRKCICA12ALDH1A1MEN1KMT2A | |
| SCHEMBL6675902 | 0.85 | BID (0.43) | ALDH1A1MEN1KMT2AHSD17B10CNR2 | |
| SCHEMBL11221193 | 0.84 | PPARA (0.46) | ALDH1A1MEN1KMT2AHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | claimed |
| US-7262208-B2 | Hydroxypropyl amides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | claimed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | claimed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | claimed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | claimed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050203096-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | claimed |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002505-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002520-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002518-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, CHAT | PRKCI 4600/4885CA12 890/4885ALDH1A1 247/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | PRKCI 4690/4885CA12 1161/4885ALDH1A1 391/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | PRKCI 4336/4885CA12 1162/4885ALDH1A1 524/4885 |
| US-20050203096-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | PRKCI 4622/4885CA12 965/4885ALDH1A1 321/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | PRKCI 4760/4885CA12 1075/4885ALDH1A1 321/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | PRKCI 4284/4885CA12 959/4885ALDH1A1 165/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | PRKCI 1616/4885CA12 4081/4885ALDH1A1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.